gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16004;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16005;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16006;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16007;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600B;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600C;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16008;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR1600F;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD16009;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16011;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16012;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16013;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16014;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site normal tissue;subject_id=BD1600A;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=cancer site diseased tissue;subject_id=PR16023;ENA-CHECKLIST=ERC000026;
